Oligonucleotides for CNS Summit on August 19-21, 2026 in Boston, United States

Oligonucleotide R and D is accelerating, driven by advances in brain shuttle technologies, RNA chemistry, and growing clinical validation from leaders such as Alnylam Pharmaceuticals, Stoke Therapeutics, and Ionis Pharmaceuticals. At the same time, major investments, including Novartis into Arrowhead Pharmaceuticals, Biogen into City Therapeutics, and Roche into Manifold Bio, underscore CNS as a key frontier for these technologies, unlocking previously undruggable targets.

Building on last year's momentum, the 6th Annual Oligonucleotides for CNS Summit will bring together 160+ experts across CNS biology, oligo chemistry, RNA science, and DMPK. Attendees will explore the latest innovations advancing nucleic acid therapies for neurodegenerative, neuromuscular, rare, epileptic, and neurodevelopmental disorders.

This summit uniquely connects stakeholders at the intersection of oligonucleotides and CNS. Join leaders from Eli Lilly, Dyne Therapeutics, Creyon Bio, and more for three days of collaboration to accelerate RNA-targeted CNS therapies.

URLs:

Tickets: https://go.evvnt.com/3603160-2?pid=10008

Brochure: https://go.evvnt.com/3603160-3?pid=10008

Time: 8:00 AM - 5:00 PM

Prices:

Drug Developer Pricing - 3 Day Pass (Conference + Workshop Day): USD 3597.00,

Drug Developer Pricing - Conference Only: USD 2699.00,

Academic Pricing - 3 Day Pass (Conference + Workshop Day): USD 2997.00,

Academic Pricing - Conference Only: USD 2299.00,

Service Provider Pricing - 3 Day Pass (Conference + Workshop Day): USD 4797.00,

Service Provider Pricing - Conference Only: USD 3399.00

Speakers: Martin Jacko, Founder and Chief Executive Officer, Aperture Therapeutics, Jimmy Weterings, Vice President and Head of Oligonucleotide Therapeutics, Bonito Bioscience, Dan Tardiff, Chief Scientific Officer, CAMP4 Therapeutics, Carl Spickett, Director, Translational Medicine, Creyon Bio, Manuel Mohr, Chief Executive Officer, D2B3, Oxana Beskrovnaya, Chief Innovation Officer, Dyne Therapeutics, Barbara Calamini, Senior Director, Eli Lilly and Co., Vinay Kumar Tiwary, Chief Managing Director, ExRNA therapeutics, Bruce Morimoto, Head, Drug Development, Fuku Biotech, David Salzman, Chief Executive Officer, Gatehouse Bio, Victoria Marshall, RNA Lead Research Analyst, Beacon Research Operations, Hanson Wade, Yacoub Habib, Chief Executive Officer, Ophidion, Inc., Ganesh Iyer, Chief Executive Officer and Founder, Opprtna Therapeutics, Hongkang Zhang, Senior Director and Head, Pain Therapeutics, Quiver Bioscience, Dan Elbaum, Chief Scientific Officer, QurAlis, Avery Yan, Founder and Chief Executive Officer, Riboway Therapeutics, Meena, Senior Vice President, Translational DMPK and Clinical Pharmacology, Stoke Therapeutics, Anindya Bhattacharya, Vice President, Head of Neuroscience, Switch Therapeutics, Irina Antonijevic, Chief Medical Officer, Trace Neuroscience, Hassan H. Fakih, Post-Doctoral Associate, RNA Therapeutics Institute, UMASS Chan Medical School, Nicole Lykens, Chief Technology Officer, Valaya Bio